Intrinsiqq
HUTCHMED (China) Ltd logo

HUTCHMED (China) Ltd Quality Score

HCM

⊜ Compare
Quality45

Valuation is the primary weakness (avg 30/100). No single area scores well.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
60/100
26.8x

25–30x, paying a growth premium

Cash Flow Multiple
0/100
-154.2x

Negative FCF, no valuation support

Revenue Growth
70/100
8.8%

5–10% CAGR, steady but not exceptional

Cash Flow Growth
0/100
Negative FCF

FCF negative, burning cash after capex

Business Quality & Capital Allocation

Share Dilution
30/100
3.0%

Diluting 2–5%, watch for SBC

Margin Trend
100/100
+88.5pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$1.24B

Net cash position, no leverage concern

2022
$631M
$27.0M
2023
$886M
$117M
2024
$836M
$113M
2025
$1.37B
$123M
CashDebt
Return on Capital
0/100
-2.8%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

HUTCHMED (China) (HCM) quality: score, margins and returns

HUTCHMED (China) (HCM) scores 45/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 7 metrics each scored 0 to 100, on -7.1% operating margins and -2.8% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is HUTCHMED (China) (HCM) a high-quality business?+

HUTCHMED (China) scores 45 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a -7.1% operating margin and a -2.8% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does HUTCHMED (China)'s quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from HCM's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where HUTCHMED (China) scores well and where it falls behind.

What is HUTCHMED (China)'s return on invested capital (ROIC)?+

HUTCHMED (China) earns about -2.8% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to HCM's margins and growth on this scorecard to judge durability.

How profitable is HUTCHMED (China)?+

HUTCHMED (China) runs an operating margin of about -7.1% and a net margin of about 83.3%. Revenue has grown at roughly 19.2% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-K filed 5 Mar 2026, covering the period ending 31 Dec 2025, as reported to the SEC. Data last refreshed 7 Jun 2026. How this is calculated.

Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with HCM

CompareIntrinsic value
TVTXTravere Therapeutics Inc.
$52.64+6.54%52
MIRMMirum Pharmaceuticals Inc.
$95.00+9.16%30
BBIOBridgeBio Pharma, Inc.
$77.89+5.21%30
ORGOOrganogenesis Holdings Inc.
$0.87+4.19%50
CPRXCatalyst Pharmaceuticals Inc.
No recent price73
OPKOpko Health Inc.
$1.77+2.91%25
NATRNature's Sunshine Products Inc.
$12.84+6.38%70
ARWRArrowhead Pharmaceuticals Inc.
$61.65+3.56%40

Held by ETFs

HCM is in 1 US ETF. The largest of them, with HCM's weight in each:

Spot a number that looks wrong? Check it in HCM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing HCM

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.